192 related articles for article (PubMed ID: 17327374)
21. The antiapoptotic protein BAG3 is expressed in thyroid carcinomas and modulates apoptosis mediated by tumor necrosis factor-related apoptosis-inducing ligand.
Chiappetta G; Ammirante M; Basile A; Rosati A; Festa M; Monaco M; Vuttariello E; Pasquinelli R; Arra C; Zerilli M; Todaro M; Stassi G; Pezzullo L; Gentilella A; Tosco A; Pascale M; Marzullo L; Belisario MA; Turco MC; Leone A
J Clin Endocrinol Metab; 2007 Mar; 92(3):1159-63. PubMed ID: 17164298
[TBL] [Abstract][Full Text] [Related]
22. Histone deacetylase inhibitors strongly sensitise neuroblastoma cells to TRAIL-induced apoptosis by a caspases-dependent increase of the pro- to anti-apoptotic proteins ratio.
Mühlethaler-Mottet A; Flahaut M; Bourloud KB; Auderset K; Meier R; Joseph JM; Gross N
BMC Cancer; 2006 Aug; 6():214. PubMed ID: 16930472
[TBL] [Abstract][Full Text] [Related]
23. A mitochondrial block and expression of XIAP lead to resistance to TRAIL-induced apoptosis during progression to metastasis of a colon carcinoma.
Ndozangue-Touriguine O; Sebbagh M; Mérino D; Micheau O; Bertoglio J; Bréard J
Oncogene; 2008 Oct; 27(46):6012-22. PubMed ID: 18560353
[TBL] [Abstract][Full Text] [Related]
24. The proteasome inhibitor bortezomib induces apoptosis in human retinoblastoma cell lines in vitro.
Poulaki V; Mitsiades CS; Kotoula V; Negri J; McMillin D; Miller JW; Mitsiades N
Invest Ophthalmol Vis Sci; 2007 Oct; 48(10):4706-19. PubMed ID: 17898295
[TBL] [Abstract][Full Text] [Related]
25. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
Pei XY; Dai Y; Grant S
Clin Cancer Res; 2004 Jun; 10(11):3839-52. PubMed ID: 15173093
[TBL] [Abstract][Full Text] [Related]
26. TRAIL/bortezomib cotreatment is potentially hepatotoxic but induces cancer-specific apoptosis within a therapeutic window.
Koschny R; Ganten TM; Sykora J; Haas TL; Sprick MR; Kolb A; Stremmel W; Walczak H
Hepatology; 2007 Mar; 45(3):649-58. PubMed ID: 17326159
[TBL] [Abstract][Full Text] [Related]
27. XIAP-targeting drugs re-sensitize PIK3CA-mutated colorectal cancer cells for death receptor-induced apoptosis.
Ehrenschwender M; Bittner S; Seibold K; Wajant H
Cell Death Dis; 2014 Dec; 5(12):e1570. PubMed ID: 25501831
[TBL] [Abstract][Full Text] [Related]
28. Cooperation between Apo2L/TRAIL and bortezomib in multiple myeloma apoptosis.
Balsas P; López-Royuela N; Galán-Malo P; Anel A; Marzo I; Naval J
Biochem Pharmacol; 2009 Mar; 77(5):804-12. PubMed ID: 19100720
[TBL] [Abstract][Full Text] [Related]
29. Bcl-2 overexpression in thyroid carcinoma cells increases sensitivity to Bcl-2 homology 3 domain inhibition.
Mitsiades CS; Hayden P; Kotoula V; McMillin DW; McMullan C; Negri J; Delmore JE; Poulaki V; Mitsiades N
J Clin Endocrinol Metab; 2007 Dec; 92(12):4845-52. PubMed ID: 17848408
[TBL] [Abstract][Full Text] [Related]
30. Regulation of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in thyroid carcinoma cells.
Poulaki V; Mitsiades CS; Kotoula V; Tseleni-Balafouta S; Ashkenazi A; Koutras DA; Mitsiades N
Am J Pathol; 2002 Aug; 161(2):643-54. PubMed ID: 12163389
[TBL] [Abstract][Full Text] [Related]
31. Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapeutic agents in gastric cancer cell lines.
Bae SH; Ryoo HM; Kim MK; Lee KH; Sin JI; Hyun MS
Oncol Rep; 2008 Apr; 19(4):1027-32. PubMed ID: 18357392
[TBL] [Abstract][Full Text] [Related]
32. Imatinib enhances human melanoma cell susceptibility to TRAIL-induced cell death: Relationship to Bcl-2 family and caspase activation.
Hamaï A; Richon C; Meslin F; Faure F; Kauffmann A; Lecluse Y; Jalil A; Larue L; Avril MF; Chouaib S; Mehrpour M
Oncogene; 2006 Dec; 25(58):7618-34. PubMed ID: 16983347
[TBL] [Abstract][Full Text] [Related]
33. Bortezomib sensitizes primary human astrocytoma cells of WHO grades I to IV for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis.
Koschny R; Holland H; Sykora J; Haas TL; Sprick MR; Ganten TM; Krupp W; Bauer M; Ahnert P; Meixensberger J; Walczak H
Clin Cancer Res; 2007 Jun; 13(11):3403-12. PubMed ID: 17545549
[TBL] [Abstract][Full Text] [Related]
34. Proteasome inhibitors sensitize glioma cells and glioma stem cells to TRAIL-induced apoptosis by PKCε-dependent downregulation of AKT and XIAP expressions.
Kahana S; Finniss S; Cazacu S; Xiang C; Lee HK; Brodie S; Goldstein RS; Roitman V; Slavin S; Mikkelsen T; Brodie C
Cell Signal; 2011 Aug; 23(8):1348-57. PubMed ID: 21440622
[TBL] [Abstract][Full Text] [Related]
35. Proteasome inhibition blocks caspase-8 degradation and sensitizes prostate cancer cells to death receptor-mediated apoptosis.
Thorpe JA; Christian PA; Schwarze SR
Prostate; 2008 Feb; 68(2):200-9. PubMed ID: 18076022
[TBL] [Abstract][Full Text] [Related]
36. Human melanoma cells selected for resistance to apoptosis by prolonged exposure to tumor necrosis factor-related apoptosis-inducing ligand are more vulnerable to necrotic cell death induced by cisplatin.
Zhang XD; Wu JJ; Gillespie S; Borrow J; Hersey P
Clin Cancer Res; 2006 Feb; 12(4):1355-64. PubMed ID: 16489094
[TBL] [Abstract][Full Text] [Related]
37. Predominant Bcl-XL knockdown disables antiapoptotic mechanisms: tumor necrosis factor-related apoptosis-inducing ligand-based triple chemotherapy overcomes chemoresistance in pancreatic cancer cells in vitro.
Bai J; Sui J; Demirjian A; Vollmer CM; Marasco W; Callery MP
Cancer Res; 2005 Mar; 65(6):2344-52. PubMed ID: 15781649
[TBL] [Abstract][Full Text] [Related]
38. Bortezomib synergizes TRAIL-induced apoptosis in gastric cancer cells.
Liu J; Qu XJ; Xu L; Zang Y; Qu JL; Hou KZ; Liu YP
Dig Dis Sci; 2010 Dec; 55(12):3361-8. PubMed ID: 20393880
[TBL] [Abstract][Full Text] [Related]
39. Bortezomib targets the caspase-like proteasome activity in cervical cancer cells, triggering apoptosis that can be enhanced by nelfinavir.
Bruning A; Vogel M; Mylonas I; Friese K; Burges A
Curr Cancer Drug Targets; 2011 Sep; 11(7):799-809. PubMed ID: 21762082
[TBL] [Abstract][Full Text] [Related]
40. The proteasome inhibitor bortezomib (Velcade) sensitizes some human tumor cells to Apo2L/TRAIL-mediated apoptosis.
Brooks AD; Ramirez T; Toh U; Onksen J; Elliott PJ; Murphy WJ; Sayers TJ
Ann N Y Acad Sci; 2005 Nov; 1059():160-7. PubMed ID: 16382051
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
